Please assess the completion status of the following clinical trial:

Trial Title: Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet Therapies

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~* Known CAD (defined as angiographic evidence of \>50% coronary artery stenosis or prior coronary revascularization) or PAD (defined as a positive ankle brachial index (ABI) or prior revascularization)~* on treatment with either aspirin (81mg/qd), aspirin (81mg/qd) plus clopidogrel (75mg/qd), or aspirin (81mg/qd) plus ticagrelor (90mg/bid) for at least 3 months per standard of care OR~* Atrial fibrillation (paroxysmal, persistent or permanent) on treatment with rivaroxaban 20 mg qd (if creatinine clearance \[CrCl\] \>50 mL/min) or 15 mg qd (if CrCl 15 - 50 mL/min) per standard of care. Patients with concomitant CAD or PAD who are also taking antiplatelet medications are not eligible. However, if these are only on oral anticoagulation with rivaroxaban (and no antiplatelet therapy) the person will be eligible.~Exclusion criteria:~* Active pathological bleeding, history of clinically significant bleeding events, or deemed at increased risk of bleeding.~* CrCL \<20 mL/min~* Any clinical indication to be on triple antithrombotic therapy (DAPT plus an oral anticoagulant)~* An acute coronary event in the past 90 days~* Prior hemorrhagic stroke or intracranial hemorrhage~* Ischemic stroke/transient ischemic attack in the past 6 months~* Chronic use of nonsteroidal anti-inflammatory drugs~* On treatment with combined P-gp and strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, lopinavir/ritonavir, ritonavir, indinavir/ritonavir, and conivaptan) or inducers (e.g., carbamazepine, phenytoin, rifampin, St. John's wort).~* Known moderate or severe hepatic impairment (Child-Pugh B and C)~* Prior hypersensitivity reaction to rivaroxaban~* On treatment with prasugrel in the past 10 days.~* Platelet count \<80x106/mL~* Hemoglobin \<10g/dL~* Hemodynamic instability~* Pregnant females \[women of childbearing age must use reliable birth control (i.e. oral contraceptives) while participating in the study\].

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- aspirin (Type: EXPERIMENTAL): Patients on aspirin 81 mg daily will be treated with adjunctive low-dose rivaroxaban (2.5 mg/bid) for 7-10 days, after which aspirin therapy will be suspended for 7-10 days.
- aspirin and clopidogrel (Type: EXPERIMENTAL): Patients on aspirin (81 mg daily) plus clopidogrel (75 mg daily) will be treated with adjunctive low-dose rivaroxaban (2.5 mg/bid) for 7-10 days, after which aspirin therapy will be suspended for 7-10 days.
- aspirin and ticagrelor (Type: EXPERIMENTAL): Patients on aspirin (81 mg daily) and ticagrelor (90 mg bid) will be treated with adjunctive low-dose rivaroxaban (2.5 mg/bid) for 7-10 days, after which aspirin therapy will be suspended for 7-10 days.
- rivaroxaban (Type: NO_INTERVENTION): A control cohort of subjects with atrial fibrillation on full dose rivaroxaban (20 mg daily) as per standard of care will be recruited and will undergo a single PD assessment.

Based on this trial design, predict the completion outcome and termination type (if applicable).